[go: up one dir, main page]

WO2007058267A1 - Proteine innovante et gene codant pour la proteine - Google Patents

Proteine innovante et gene codant pour la proteine Download PDF

Info

Publication number
WO2007058267A1
WO2007058267A1 PCT/JP2006/322879 JP2006322879W WO2007058267A1 WO 2007058267 A1 WO2007058267 A1 WO 2007058267A1 JP 2006322879 W JP2006322879 W JP 2006322879W WO 2007058267 A1 WO2007058267 A1 WO 2007058267A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
amino acid
gene
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/322879
Other languages
English (en)
Japanese (ja)
Other versions
WO2007058267A8 (fr
Inventor
Kenichi Mikitani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2007058267A1 publication Critical patent/WO2007058267A1/fr
Publication of WO2007058267A8 publication Critical patent/WO2007058267A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Definitions

  • the present invention relates to a novel protein and a gene encoding the same.
  • Non-Patent Document 2 Schultz, J., SAM as a protein interaction domain involved in developm ental regulation, Protein Sci., 1997, 6, 249-253
  • Non-Patent Document 3 Kim, C.A. and Bowie, J.U., SAM domains: Uniform structure, diversit y of lunction, Trends Biochem. Sci., 2003, 28, 625-628
  • the present invention firstly provides a novel protein related to ontogeny, a gene encoding the protein, a recombinant vector containing the gene, a transformant containing the recombinant vector, and an antibody against the protein Alternatively, an object is to provide a fragment thereof.
  • a second object of the present invention is to provide a screening method for substances that affect ontogeny.
  • the present invention provides the following protein, gene, recombinant vector, transformant, antibody or fragment thereof, and screening method.
  • a transformant comprising the recombinant vector according to (6).
  • the test substance is an affinity reciprocal between the protein described in (3) and Bax inhibitor-1
  • a method for screening a substance that affects ontogeny comprising the step of determining whether or not the action can be suppressed or promoted and screening the test substance capable of suppressing or promoting the affinity interaction as a substance that affects ontogeny .
  • a novel protein related to ontogeny a gene encoding the protein, a recombinant vector containing the gene, a transformant containing the recombinant vector, and an antibody against the protein or its Fragments are provided.
  • the present invention also provides a method for screening for substances that affect ontogeny.
  • FIG. 1 is a diagram showing the genomic structures of human gene 1 and mouse gene 1.
  • FIG. 2 is a graph showing the expression of human gene 1 in tissues such as brain, kidney, lung, muscle, placenta, small intestine, testis, adrenal gland, salivary gland, spleen, and stomach.
  • FIG. 3 shows the results of observing the localization of a GFP-fused human gene 1 product in COS-7 cells using a fluorescence microscope.
  • FIG. 4 is a diagram showing the detection result of interaction between human gene 1 products by co-immunoprecipitation method.
  • FIG. 5 is a diagram showing the results of detecting the interaction between human gene 1 products by the mammalian cell two-hybrid method.
  • FIG. 6 is a view showing the detection results of the interaction between the human gene 1 product and the human Bax inhibitor 1 gene product by the mammalian cell two-hybrid method.
  • FIG. 7 is a diagram showing the detection result of human gene 1 product by Western blotting using anti-gene 1 antibody.
  • FIG. 8 is a block diagram of a GFP human gene 1 vector.
  • FIG. 9 is a block diagram of a FLAG human gene 1 vector.
  • FIG. 10 is a block diagram of the HA-human gene 1 vector.
  • FIG. 11 is a block diagram of a GAL4 human gene 1 vector.
  • FIG. 12 is a block diagram of a VP16 human gene 1 vector.
  • FIG. 13 is a block diagram of a VP16 human Bax inhibitor-1 gene vector.
  • FIG. 14 is a block diagram of a mouse gene 1 gene targeting vector.
  • the protein of the present invention is a protein shown in the following (a), (b), (c) or (d).
  • protein (a) a protein having an amino acid sequence ability described in SEQ ID NO: 2 or 4 (hereinafter sometimes referred to as “protein (a)”)
  • protein (b) In the amino acid sequence set forth in SEQ ID NO: 2 or 4, one or more amino acids are deleted, substituted or added, and it is also an amino acid sequence that is essential for ontogeny (hereinafter referred to as “protein (b)”) There may be cases.)
  • protein (c) a protein having an affinity interaction with the protein shown in (a) above, wherein one or more amino acids are deleted, substituted or added in the amino acid sequence shown in SEQ ID NO: 2 or 4 (Hereafter referred to as “protein (c)”!
  • protein (d) A protein having an amino acid sequence ability in which one or more amino acids are deleted, substituted or added in the amino acid sequence described in SEQ ID NO: 2 or 4, and has an affinity interaction with Bax inhibitor-1 (hereinafter referred to as “protein ( d) "may occur.)
  • the protein having the amino acid sequence ability described in SEQ ID NO: 2 is a protein derived from human, and the protein consisting of the amino acid sequence described in SEQ ID NO: 4 is a mouse-derived protein.
  • Protein (a) is an essential protein for ontogeny. Protein (a) is essential for ontogeny especially in the embryonic period, and if the gene encoding the protein comprising the amino acid sequence described in SEQ ID NO: 2 becomes homo-deficient in the human genome, the fertilized egg The normal development process cannot be achieved and the human fetus is fatal. In addition, if the gene encoding the protein having the amino acid sequence shown in SEQ ID NO: 4 becomes homo-deficient in the mouse genome, the fertilized egg cannot go through a normal development process, and the mouse fetus It will be lethal. In addition, if it is a hetero deficiency type, a human fetus and a mouse fetus will not be lethal.
  • Protein (a) exhibits an affinity interaction with another protein (a).
  • the affinity interaction of protein (a) is considered to be involved in ontogeny, especially in embryonic development.
  • “Affinity interaction between proteins (a)” means protein (a) It means both direct binding between proteins and indirect binding between proteins (a) via other substances, preferably direct binding between proteins (a).
  • Protein (a) exhibits an affinity interaction with Bax inhibitor-1.
  • the affinity interaction between protein (a) and Bax inhibitor-1 is thought to be involved in ontogeny, particularly in embryonic development.
  • “Friendly interaction between protein (a) and Bax inhibitor-1” refers to direct binding between protein (a) and Bax inhibitor-1 and protein (a) via other substances. This also means a shift in indirect binding with Bax inhibitor-1, but preferably means direct binding between protein (a) and Bax inhibitor-1.
  • Bax inhibitor-1 inhibits the action of Bax, a factor that induces apoptosis, and suppresses cell death.
  • proteins that interact with Bax inhibitor-1 include Be 1-2 and Bel-XL.
  • the amino acid sequence of human-derived Bax inhibitor-1 is shown in SEQ ID NO: 6, and the base sequence of the DNA encoding it is shown in SEQ ID NO: 5.
  • the 73rd amino acid force and the 140th amino acid moiety contain a peptide motif characteristic of a signal transduction factor called a SAM (Sterile Alpha Motif) domain.
  • SAM Sterile Alpha Motif
  • the Ser residue of amino acid 52 is included in the motif characteristic of the MAP kinase substrate, and the region from amino acid 247 to amino acid 250 (Pro-Pro-Leu-Pro) is an SH3 binding region motif.
  • the SAM domain is a peptide domain structure of about 70 amino acids, is found in eukaryotic gene products from yeast to humans, and is thought to mediate protein-protein interactions. ing. In some SAM domains, RNA binding ability, lipid binding ability, etc. have been reported.
  • MAP kinase is a serine-threonine kinase that is ubiquitous in eukaryotes and plays an important role in cell proliferation, differentiation, apoptosis, morphogenesis, and the like.
  • a MAP kinase substrate is a protein that is activated or inactivated by being phosphorylated by MAP kinase.
  • the SH3 (Src homology 3) binding domain is a domain that binds to the SH3 domain, which is a functional domain in the oncogenic tyrosine kinase gene product Src.
  • Pro- Xaal- Xaa2- ro X aa 2 is usually a hydrophobic amino acid.
  • the Src gene product is thought to play an important role in embryonic development and cell proliferation.
  • the number and position of amino acids deleted, substituted or added to the amino acid sequence shown in SEQ ID NO: 2 or 4 retains the function of protein (a), which is essential for ontogeny.
  • the number is not particularly limited as long as it is one or more, preferably one or several.
  • the specific range for deletion is usually 1 to 40, preferably 1 to 20, more preferably 1 to 10, and the specific range for substitution is usually 1 to 20, preferably 1 to 10. 10, more preferably 1-5, and the specific range for addition is usually 1-10, preferably 1-5, more preferably 1-2.
  • the amino acid sequence of protein (b) has a homology of usually 70% or more, preferably 80% or more, more preferably 90% or more with the amino acid sequence of protein (a).
  • protein (a) is introduced with mutations such as deletion, substitution and addition. It includes proteins that exist in nature and proteins that have been artificially introduced with mutations such as deletions, substitutions, and additions. Naturally occurring proteins with mutations such as deletions, substitutions and additions include, for example, mammals (eg, humans, monkeys, bushes, hidges, goats, horses, pigs, rabbits, And the like (including proteins that can be generated by polymorphism in these mammals).
  • mammals eg, humans, monkeys, bushes, hidges, goats, horses, pigs, rabbits, And the like (including proteins that can be generated by polymorphism in these mammals).
  • the number and position of amino acids deleted, substituted, or added to the amino acid sequence shown in SEQ ID NO: 2 or 4 indicates an affinity interaction with another protein (a) (
  • the number is not particularly limited as long as the function of a) is maintained, and the number is one or more, preferably one or several.
  • the specific range for deletion is usually 1 to 40, preferably 1 to 20, more preferably 1 to: LO, and the specific range for substitution is usually 1 to 20, preferably 1.
  • ⁇ : LO, more preferably 1-5, and the specific range for addition is usually 1-10, preferably 1-5, more preferably 1-2.
  • the amino acid sequence of protein (c) usually has a homology of 70% or more, preferably 80% or more, more preferably 90% or more with the amino acid sequence of protein (a).
  • the 1st to 62nd amino acids are amino acids. Even if one or more amino acids are deleted, substituted, or added in the sequence part or the amino acid sequence part of the 159th to 478th amino acids, the protein interacts with other proteins (a). The function of protein (a) is retained.
  • the amino acid sequence portion having 1st to 62nd amino acid force is present on the N-terminal side of the SAM domain, includes a MAP kinase basic motif, and is a portion having a relatively large difference between human and mouse.
  • the amino acid sequence part of the 478th amino acid is located on the C-terminal side of the SAM domain, contains the SH3 binding domain, and has relatively high homology between humans and mice! , Part.
  • protein () in addition to a protein in which mutations such as deletion, substitution, and addition have been artificially introduced into protein (a), natural mutations in which mutations such as deletion, substitution, and addition have been introduced.
  • proteins that are present in humans and proteins into which mutations such as deletions, substitutions, and additions have been artificially introduced are also included.
  • Naturally occurring proteins with mutations such as deletions, substitutions and additions include, for example, mammals (eg, humans, monkeys, bushes, hidges, goats, horses, pigs, rabbits, And the like (including proteins that can be generated by polymorphism in these mammals).
  • the number and position of amino acids deleted, substituted, or added to the amino acid sequence shown in SEQ ID NO: 2 or 4 is a protein that exhibits an affinity interaction with Bax inhibitor-1 ( The number is not particularly limited as long as the function of a) is maintained, and the number is one or more, preferably one or several.
  • the specific range for deletion is usually 1 to 40, preferably 1 to 20, more preferably 1 to: L0, and the specific range for substitution is usually 1 to 20, preferably 1 ⁇ : L0, more preferably 1-5, and the specific range for addition is usually 1-10, preferably 1-5, more preferably 1-2.
  • the amino acid sequence of the protein (d) has a homology of usually 70% or more, preferably 80% or more, more preferably 90% or more with the amino acid sequence of the protein (a).
  • the amino acid sequence portion having the amino acid strength of 1 to 232 or the amino acid sequence portion having the amino acid strength of 264 to 478 is missing one or more amino acids. Even if it is lost, substituted or added, the function of the protein (a), which shows an affinity interaction with Bax inhibitor-1, is retained.
  • the amino acid sequence portion consisting of amino acids 1 to 232 contains a SAM domain and a MAP kinase substrate motif
  • the amino acid sequence portion consisting of amino acids 264 to 478 is a portion containing a relatively large amount of hydrophobic amino acids, including the SH3 binding region domain, and a portion containing a relatively large amount of hydrophobic amino acids.
  • protein () in addition to a protein in which mutations such as deletion, substitution, addition, etc. are artificially introduced into protein (a), a mutation, such as deletion, substitution, addition, etc., is naturally introduced.
  • proteins that are present in humans and proteins into which mutations such as deletions, substitutions, and additions have been artificially introduced are also included.
  • Naturally occurring proteins with mutations such as deletions, substitutions and additions include, for example, mammals (eg, humans, monkeys, bushes, hidges, goats, horses, pigs, rabbits, And the like (including proteins that can be generated by polymorphism in these mammals).
  • the animal derived from Bax inhibitor-1 in which protein (d) exhibits an affinity interaction is not particularly limited. However, when protein (d) is a naturally occurring protein, a protein ( If the animal derived from d) and the animal derived from Bax inhibitor-1 are of the same species, protein (d) is considered to exhibit a high affinity interaction with Bax inhibitor-1.
  • the protein (a), (b), (c) or (d) includes a protein to which a sugar chain has been added and a shift of the protein to which the sugar chain has been added.
  • the type and position of the sugar chain added to the protein varies depending on the type of host cell used in the production of the protein. Any host cell can be used for the protein with the added sugar chain. Proteins are also included.
  • protein), (b) or (d) includes pharmaceutically acceptable salts thereof.
  • the gene encoding protein), (b), (c) or (d) is, for example, mammalian brain, kidney, lung, muscle, placenta, small intestine, testis, adrenal gland, salivary gland, spleen, stomach, etc.
  • a cDNA library is prepared using the mRNA extracted from the tissue strength of each, and a clone containing the target DNA is screened from the cDNA library using probes synthesized based on the nucleotide sequences described in SEQ ID NO: 1 or 3, respectively. Can be obtained. The following explains each step of cDNA library preparation and screening of clones containing the target DNA.
  • RNA is obtained by the affinity column method, batch method, etc. using cellulose or poly-sepharose. At this time, poly (A +) RNA (mRNA) may be fractionated by sucrose density gradient centrifugation or the like.
  • single-stranded cDNA is synthesized using an oligo dT primer and reverse transcriptase, and then double-stranded cDNA is synthesized from the single-stranded cDNA.
  • the double-stranded cDNA thus obtained is incorporated into an appropriate cloning vector to prepare a recombinant vector, and the recombinant vector is used to transform host cells such as Escherichia coli, which have tetracycline resistance and ampicillin resistance.
  • a cDNA library can be obtained.
  • the cloning vector for preparing the cDNA library is not particularly limited as long as it can replicate autonomously in the host cell.
  • a phage vector or a plasmid vector can be used.
  • Escherichia coli can be used.
  • Transformation of host cells such as Escherichia coli is carried out by a method in which a recombinant vector is coated on a competent cell prepared in the presence of salt calcium salt, salt magnesium or salt rubidium. Can do.
  • a plasmid it is preferable to contain a drug resistance gene such as tetracycline or ampicillin.
  • a primer is synthesized based on the nucleotide sequence described in SEQ ID NO: 1 or 3, and this is used to perform a polymerase chain reaction (PCR). An amplified fragment is obtained. PCR amplified fragments can be subcloned using an appropriate plasmid vector.
  • the primer set used for PCR is not particularly limited, and can be designed based on the nucleotide sequence described in SEQ ID NO: 1 or 3.
  • the target DNA can be obtained by performing a hybridization or plaque hybridization.
  • a PCR-amplified fragment labeled with an isotope eg, 32 P, 35 S
  • piotin e.g., digoxigenin
  • alkaline phosphatase e.g., alkaline phosphatase
  • a clone containing the target DNA can be obtained by expression screening such as immunoscreening using an antibody.
  • the obtained DNA base sequence is obtained by cleaving the DNA fragment as it is or with a suitable restriction enzyme, etc., and then incorporating the DNA fragment into a vector by a conventional method, for example, a commonly used base sequence analysis method, such as Maxam Gilbert's chemistry. It can be determined using the modification method or the dideoxynucleotide chain termination method.
  • a base sequence analyzer such as 373A DNA Sequencer (manufactured by Perkin Elmer) is usually used.
  • the gene encoding protein), (b), (c) or (d) includes an open reading frame and a stop codon located at the 3 'end thereof.
  • the gene encoding protein), (b), (c) or (d) can contain an untranslated region (UTR) at the 5 ′ end and Z or 3 ′ end of the open reading frame.
  • Examples of the gene encoding the protein having the amino acid sequence ability described in SEQ ID NO: 2 include a gene containing DNA consisting of the 19th to 1452th base sequences in the base sequence described in SEQ ID NO: 1.
  • the open reading frame is located at the 19th to 1452th base sequence
  • the translation initiation codon is located at the 19th to 21st base sequence
  • the stop codon is from 1453 to Located at the 1455th nucleotide sequence.
  • the base sequence of the gene encoding the protein consisting of the amino acid sequence described in SEQ ID NO: 2 is not particularly limited as long as it encodes the protein.
  • the base sequence of the open reading frame is the base sequence described in SEQ ID NO: 1. Of these, the base sequence is not limited to the 19th to 1452st positions.
  • Examples of the gene encoding the protein having the amino acid sequence ability described in SEQ ID NO: 4 include a gene containing DNA consisting of the 46th to 1479th base sequences of the base sequence described in SEQ ID NO: 3.
  • the open reading frame is located at the 46th to 1479th base sequence
  • the translation initiation codon is located at the 46th to 48th base sequence
  • the stop codon is from 1480 to Located at base 1482
  • the base sequence of the gene encoding the protein having the amino acid sequence ability described in SEQ ID NO: 4 is not particularly limited as long as it encodes the protein.
  • the base sequence of the open reading frame is the base sequence described in SEQ ID NO: 4. Of these, it is not limited to the 46th to 1479th nucleotide sequences.
  • the gene encoding protein), (b), (c) or (d) can also be obtained by chemical synthesis according to the base sequence.
  • a commercially available DNA synthesizer for example, a DNA synthesizer using the thiophosphite method (manufactured by Shimadzu Corporation), or a DNA synthesizer using the phosphoramidite method (manufactured by Perkin 'Elma Corporation) Can be used.
  • the gene encoding protein (c), (c) or (d) is, for example, a stringent to a DNA complementary to the DNA comprising the 19th to 1452th base sequences of the base sequence described in SEQ ID NO: 1. Including DNA that hybridizes under mild conditions, or DNA that hybridizes under stringent conditions to DNA complementary to DNA consisting of the 46th to 1479th nucleotide sequences of the nucleotide sequence set forth in SEQ ID NO: 3. Gene.
  • “Stringent conditions” include, for example, conditions of 42 ° C., 2 ⁇ SSC and 0.1% SDS, preferably conditions of 65 ° C., 0.1 ⁇ SSC and 0.1% SDS.
  • the DNA that hybridizes under stringent conditions to DNA complementary to the DNA consisting of the 19th to 1452th base sequences of the base sequence set forth in SEQ ID NO: 1 includes 19 of the base sequence set forth in SEQ ID NO: 1.
  • the DNA that hybridizes under stringent conditions to DNA complementary to the DNA that also has the second base sequence ability is at least 70% or more of the DNA consisting of the 46th to 1479th base sequences of the base sequence described in SEQ ID NO: 3.
  • a DNA having a homology of preferably 80% or more, more preferably 90% or more is mentioned.
  • the gene encoding protein (b), (c) or (d) is artificially added to the gene encoding protein (a) using a known method such as site-directed mutagenesis. It can also be obtained by introducing mutations.
  • mutation introduction kits such as Mutant-K (TAKARA), Mutant-G (TAKARA), TAKARA LA PCR in vitro M Can be performed using the utagenesis series kit.
  • a gene whose base sequence has already been determined can be obtained by chemical synthesis according to the base sequence.
  • the protein), (b), (c) or (d) can be produced, for example, by expressing a gene encoding each protein in a host cell according to the following steps.
  • DNA fragment of appropriate length that contains the coding region of the protein of interest.
  • DNA with a base substitution is prepared so that the base sequence of the coding region of the target protein becomes the optimal codon for expression in the host cell.
  • a recombinant protein can be produced by inserting this DNA fragment downstream of the promoter of an appropriate expression vector, and the desired protein can be produced by introducing the recombinant vector into an appropriate host cell.
  • a transformant is obtained.
  • the above DNA fragment must be incorporated into a vector so that its function can be exerted.
  • the vector is not only a propeller motor, but also a cis element such as an enhancer, splicing signal, poly A addition signal, selection A marker (for example, dihydrofolate reductase gene, ampicillin resistance gene, neomycin resistance gene), ribosome binding sequence (SD sequence) and the like can be contained.
  • the expression vector is not particularly limited as long as it can replicate autonomously in a host cell, and for example, a plasmid vector, a phage vector, a virus vector, and the like can be used.
  • plasmid vectors include plasmids derived from E.
  • coli eg, pRSET, pBR322, pBR325, pUC118, pUC119, pUC18, pUC19
  • plasmids derived from Bacillus subtilis eg, pUB110, pTP5
  • yeast eg, YEpl3 YEp24, YCp50
  • phage vectors include, for example, ⁇ phage (for example, Charon4A, Charon21A, EMBL3, EMBL4, gtl0, gtll, ⁇ ZAP)
  • viral vectors include, for example, retro Examples include viruses, animal viruses such as vaccinia virus, and insect viruses such as baculovirus.
  • any of prokaryotic cells, yeast, animal cells, insect cells, plant cells and the like may be used as long as the target gene can be expressed.
  • bacterium for example, Escherichia coli and other Escherichia genus, Bacillus subtilis and other Bacillus genus, Pseudomonas putida and Pseudomonas putida genus Bacteria belonging to the genus Rhizobium such as Rhizobium meliloti can be used as host cells.
  • Escherichia coli BL21, Escherichia coli XL1-Blue, Escherichia coli XL2-Blue, Esch ericnia coli DH1, Escherichia coli K12, Escherichia coli JM109, Escherichia coli HB 101, etc., Bacillus subtilis MI 114, Bacillus subtilis Bacillus subtilis such as 207-21 can be used as the host cell.
  • the promoter is not particularly limited as long as it can be expressed in bacteria such as Escherichia coli.
  • promoters derived from E. coli and phages such as motors and P promoters
  • promoters such as tac promoter, lacT7 promoter, let I promoter can also be used.
  • the method for introducing the recombinant vector into the bacterium is not particularly limited as long as it is a method capable of introducing DNA into the bacterium, and for example, a method using calcium ions, an electoporation method, or the like can be used.
  • yeast When yeast is used as a host cell, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, etc. can be used as host cells.
  • the promoter in this case is not particularly limited as long as it can be expressed in yeast.
  • gall promoter, gallO promoter, heat shock protein promoter, MFa 1 promoter, PH05 promoter, PGK promoter, GAP promoter, ADH promoter AOX1 promoter, etc. can be used.
  • the method for introducing the recombinant vector into yeast is not particularly limited as long as it is a method capable of introducing DNA into yeast, and for example, the electopore position method, the spheroplast method, the lithium acetate method and the like can be used.
  • monkey cells such as COS-7, Vero, Chinese nomstar ovary cells (CHO cells), mouse L cells, rat GH3, and human FL cells are used as host cells.
  • the promoter in this case is not particularly limited as long as it can be expressed in animal cells.
  • SRa promoter SV40 promoter, LTR (Long Terminal Repeat) promoter, CMV promoter, human cytomegalovirus early gene Promoters can be used.
  • the method for introducing a recombinant vector into an animal cell is not particularly limited as long as it is a method capable of introducing DNA into an animal cell.
  • the electopore position method, the calcium phosphate method, the lipofection method and the like can be used.
  • Spodoptera frugiperda ovary cells When an insect cell is used as a host, Spodoptera frugiperda ovary cells, Trichoplusia ni ovary cells, silkworm ovary-derived cultured cells, and the like can be used as host cells.
  • Spodopt era frugiperda ovary cells such as S19, Sf21 etc., Trichoplusia ni ovary cells Hi gh 5, ⁇ - ⁇ -5 ⁇ 1-4 (manufactured by Invitrogen), etc.
  • the method for introducing a recombinant vector into an insect cell is not particularly limited as long as DNA can be introduced into an insect cell.
  • a calcium phosphate method, a lipofusion method, an electopore position method, or the like can be used.
  • Transformants into which a recombinant vector incorporating a DNA encoding the target protein has been introduced are cultured according to a conventional culture method.
  • the transformant can be cultured according to a conventional method used for culturing host cells.
  • the medium As a medium for culturing a transformant obtained using a microorganism such as Escherichia coli or yeast as a host cell, the medium contains a carbon source, a nitrogen source, inorganic salts and the like that can be assimilated by the microorganism. As long as the medium can efficiently cultivate the culture medium, a combination of a natural medium and a synthetic medium may be used.
  • the carbon source carbohydrates such as glucose, fructose, sucrose, and starch, organic acids such as acetic acid and propionic acid, and alcohols such as ethanol and propanol can be used.
  • Nitrogen sources include ammonia, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium salts of organic acids such as ammonium phosphate, peptone, meat extract. Yeast extract, corn steep liquor, casein hydrolyzate and the like can be used.
  • machine salt examples include monopotassium phosphate, dipotassium phosphate, magnesium phosphate, magnesium sulfate, sodium chloride salt, ferrous sulfate, manganese sulfate, copper sulfate, and calcium carbonate.
  • the transformant obtained by using microorganisms such as Escherichia coli and yeast as host cells is cultured under aerobic conditions such as shaking culture or aeration and agitation culture.
  • the culture temperature is usually 25 to 37 ° C
  • the culture time is usually 16 to 24 hours
  • the pH is maintained at 6.0 to 8.0 during the culture period.
  • the pH can be adjusted using an inorganic acid, organic acid, alkaline solution, urea, calcium carbonate, ammonia or the like.
  • antibiotics such as ampicillin and tetracycline may be added to the medium as needed during the culture.
  • an inducer may be added to the medium as necessary.
  • cultivate a microorganism transformed with an expression vector using the lac promoter cultivate a microorganism transformed with an expression vector using trp promoter, such as isopropyl ⁇ -D-thiogalatatopyranoside. When doing so, indoleacrylic acid or the like may be added to the medium.
  • a medium for culturing a transformant obtained by using animal cells as host cells RPMI1640 medium, Eagle's MEM medium, DMEM medium, Ham F12 medium, Ham F12K medium, or these mediums may be used.
  • a medium supplemented with fetal calf serum or the like can be used.
  • Transformants are usually cultured at 37 ° C for 1 to 3 days in the presence of 5% CO. Also, when culturing
  • antibiotics such as kanamycin, penicillin and streptomycin may be added to the medium.
  • Transformants obtained using insect cells as host cells
  • TNM-FH medium Pharmingen
  • Sf-900 II SFM medium G3 ⁇ 4co BRL
  • Manufactured ExCell400
  • ExCell405 manufactured by JRH Biosciences
  • Transformants are usually cultured at 20-28 ° C for 2-4 days.
  • an antibiotic such as gentamicin may be added to the medium as needed during the culture.
  • the target protein can also be expressed as a secreted protein or a fusion protein.
  • proteins to be fused include 13-galatatosidase, protein A, IgG binding region of protein A, chloramphee-chol'acetylyltransferase, poly (Arg), poly (Glu), protein G, maltose binding protein, dartathione S-transferase, polyhistidine chain (His-tag), S peptides, DNA-binding protein domains, Tac antigens, thioredoxin, green 'fluorescent' protein (GFP), and the like.
  • the target protein By collecting the target protein from the transformant culture, the target protein can be obtained.
  • the “culture” includes deviations of culture supernatant, cultured cells, cultured cells, cells or disrupted cells.
  • the target protein When the target protein accumulates in the cells of the transformant, the cells in the culture are collected by centrifuging the culture, and the cells are washed and then disrupted. Extract the protein. When the target protein is secreted outside the transformant, use the culture supernatant as it is, or remove cells or cells from the culture supernatant by centrifugation or the like.
  • the protein (a), (b), (c) or (d) thus obtained can be obtained by solvent extraction method, salting-out method using ammonium sulfate, desalting method, precipitation method using organic solvent, jetylaminoethyl (DEAE ) -Sepharose, ion exchange chromatography method, hydrophobic chromatography method, gel filtration method, fineness chromatography method and the like.
  • Protein (a), (b), (c) or (d) is based on the amino acid sequence based on the Fmoc method (fluoromethyloxycarbon method), tBoc method (tbutyl). It can also be produced by chemical synthesis methods such as the oxycarbon method. At this time, a commercially available peptide synthesizer can be used.
  • the antibody or fragment thereof of the present invention is an antibody or fragment thereof capable of reacting with the protein (a), (b), (c) or (d).
  • “antibodies” include both monoclonal antibodies and polyclonal antibodies, and “monoclonal antibodies and polyclonal antibodies” include all classes of monoclonal antibodies and polyclonal antibodies.
  • “antibodies” are obtained by immunizing animals such as rabbits and mice with antisera obtained by immunizing protein (a), (b), (c) or (d), human antibodies, or genetic recombination. Also included are humanized antibodies.
  • Antibody fragments include Fab fragments, F (ab) ′ fragments, single-chain antibodies (scFv) and the like.
  • the antibody of the present invention or a fragment thereof can be prepared by using the protein), (b), (c) or (d) as an immunizing antigen.
  • immunizing antigens include, for example, disrupted cells or tissues expressing (0 protein), (b), (c) or (d) or purified products thereof, and (ii) gene recombination techniques.
  • a recombinant protein expressed by introducing a gene encoding protein (a), (b), (c) or (d) into a host such as Escherichia coli, insect cells or animal cells, (m) chemically synthesized Peptides etc. can be used.
  • mammals such as rats, mice, guinea pigs, rabbits, hidges, horses, horseshoes, etc. are immunized using an immunizing antigen. It is preferable that rabbits use rabbits because immunized animals can easily produce antibodies.
  • an immune assistant such as Freund's complete adjuvant.
  • an immunity assistant Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), aluminum hydroxide gel, and the like can be used.
  • the dose of antigen per mammal can be set as appropriate according to the type of mammal, but in the case of rabbits it is usually 10 to: LOOO / zg.
  • the administration site is, for example, intravenous, intradermal, subcutaneous, intraperitoneal or the like. Immunization is usually performed every few days to several weeks, preferably 5 days to 3 weeks, for a total of 3 to 8 times, preferably 4 to 6 times. Then, 10 to 14 days after the last immunization day, the antibody titer against the protein (a), (b), (c) or (d) is measured, blood is collected after the antibody titer is increased, and antiserum is collected. obtain. Antibody titer can be measured by enzyme immunoassay (ELISA), radioimmunoassay (RIA), or the like.
  • ELISA enzyme immunoassay
  • RIA radioimmunoassay
  • Antiserum ability When purification of the antibody is required, a known method such as salting out with ammonium sulfate, gel chromatography, ion exchange chromatography, and affinity chromatography is appropriately selected. Or they can be used in combination.
  • a mammal is immunized with an immunizing antigen as in the case of a polyclonal antibody, and antibody-producing cells are collected 3 to 4 days after the final immunization.
  • antibody-producing cells include spleen cells, lymph node cells, thymocytes, and peripheral blood cells, and spleen cells are generally used.
  • Myeloma cells to be fused with antibody-producing cells include human and mouse mammals
  • a cell line derived from a product and generally available can be used.
  • Preferred cell lines are those that have drug selectivity and cannot survive in a selective medium (for example, HAT medium) in an unfused state, but can survive only in a state fused with antibody-producing cells. Better ,.
  • myeloma cells include mouse myeloma cell lines such as P3X63-Ag.8.Ul (P3Ul), P3 / NSI / 1-Ag4-1, Sp2 / 0-Agl4.
  • antibody-producing cells and myeloma cells are mixed in a predetermined ratio (for example, 3: 1 to 1.5: 1) in animal cell culture media such as serum-free DMEM, RPMI-1640 medium, etc. And the fusion reaction is carried out in the presence of a cell fusion promoter such as polyethylene glycol, or by electric pulse treatment (eg, electoral positioning).
  • a cell fusion promoter such as polyethylene glycol, or by electric pulse treatment (eg, electoral positioning).
  • the cells are cultured using a selective medium, and the desired hyperidoma is selected. Subsequently, the culture supernatant of the grown hyperidoma is screened for the presence of the antibody of interest.
  • Hypridoma screening is not particularly limited as long as it is in accordance with a normal method. For example, a part of the culture supernatant contained in the wells grown as robin and hybridoma can be collected and screened by enzyme immunoassay (ELISA), radioimmunoassay (RIA) and the like.
  • Cloning of the hybridoma can be performed, for example, by limiting dilution, soft agar, fibrin gel, fluorescence excitation cell sorter, or the like, and finally a hyperidoma that produces a monoclonal antibody is obtained.
  • a normal cell culture method or the like can be used as a method for collecting the acquired monoclonal antibody monoclonal antibody.
  • a normal cell culture method for example, Hypridoma is used in animal cell culture media such as RPMI-1640 medium containing 10 to 20% fetal calf serum and MEM medium under normal culture conditions (for example, 37 ° C, 5% CO concentration).
  • animal cell culture media such as RPMI-1640 medium containing 10 to 20% fetal calf serum and MEM medium under normal culture conditions (for example, 37 ° C, 5% CO concentration).
  • Monoclonal antibodies can also be obtained from the culture supernatant strength. It is also possible to transplant a hyperidoma into the abdominal cavity of a mouse or the like, collect ascites after 10 to 20 days, and obtain a monoclonal antibody from the ascites.
  • the monoclonal antibody When purification of the monoclonal antibody is required, a known method such as salting out with ammonium sulfate, gel chromatography, ion exchange chromatography, affinity chromatography, or the like is appropriately selected or These can be used in combination.
  • a known method such as salting out with ammonium sulfate, gel chromatography, ion exchange chromatography, affinity chromatography, or the like is appropriately selected or These can be used in combination.
  • a known method such as salting out with ammonium sulfate, gel chromatography, ion exchange chromatography, affinity chromatography, or the like is appropriately selected or These can be used in combination.
  • a human antibody or a humanized antibody When the monoclonal antibody is used for human administration (antibody therapy), it is preferable to use a human antibody or a humanized antibody in order to reduce immunogenicity.
  • Human antibodies or humanized antibodies can be obtained, for example, by preparing mice or hybridomas using
  • a transgenic animal having a repertoire of human antibody genes is immunized with an antigen protein, a protein-expressing cell, or a solution thereof to obtain antibody-producing cells, which are fused with myeloma cells.
  • a human antibody against the protein of interest can be obtained using the thus-prepared hybridoma (see International Publication Nos. W09 2-03918, W093-2227, WO94-02602, W096-33735 and WO96-34096).
  • a phage displaying an antibody that binds to a protein serving as an antigen, a protein-expressing cell, or a lysate thereof, from an antibody library in which a plurality of different human scFvs are displayed on a phage.
  • the scFv that binds to the protein of interest can be selected (Griffiths. Et al., EMBO J. 12, 725-734, 1993).
  • the test substance determines whether or not the affinity interaction between the proteins (a) or (c) can be suppressed or promoted, and the affinity interaction is suppressed or Includes screening of test substances that can be accelerated as substances that affect ontogeny.
  • Affinity interaction between proteins (a) or (c) is considered to be involved in ontogeny, particularly ontogeny in the embryonic period, so affinity between proteins (a) or (c) By selecting substances that can suppress or promote interactions, substances that may affect ontogeny, particularly ontogeny during the embryonic period, can be screened.
  • test substance can suppress or promote the affinity interaction between the proteins (a) or (c) can be determined, for example, as follows, but the determination method is limited to this. It is not a thing.
  • the protein (a) or (c) After contacting the protein (a) or (c) with another protein (a) or (c) in the presence or absence of the test substance, the protein (a) or (c) is bound to each other. Measure the amount and compare the amount of binding in the presence of the test substance with the amount of binding in the absence of the test substance. As a result, the amount of binding in the presence of the test substance is greater than the amount of binding in the absence of the test substance. If it is less, it can be determined that the test substance can suppress the binding between the proteins (a) and (c). On the other hand, if the amount of binding in the presence of the test substance is greater than the amount of binding in the absence of the test substance, it can be determined that the test substance can promote the binding between the proteins (a) or (c).
  • the substance capable of suppressing or promoting the binding between proteins (a) or (c) may be a substance acting on one protein (a) or (c)! /, And both proteins It may be a substance that acts on (a) or (c). Further, the substance capable of suppressing the binding between the proteins (a) or (c) may be a substance capable of suppressing the binding between the proteins (a) or (c) in a dissociated state or in a bound state. It may be a substance capable of dissociating proteins (a) or (c).
  • Protein (a) or (c) and another protein (a) or (c) may be contacted in vitro or in vivo.
  • a cell or tissue that expresses the target protein or extracted endogenous protein (ii) the target protein A recombinant vector capable of expressing the quality can be introduced into a host cell to produce a transformant, and a recombinant protein extracted from the culture of the transformant, () a chemically synthesized peptide, or the like can be used.
  • a recombinant vector capable of expressing the target protein is introduced into the host cell.
  • a recombinant protein or the like present in the transformant produced by the introduction can be used.
  • Mutants, wild-type or mutant derivatives, fusion proteins of wild-type or mutants with other proteins or peptides, and the like can be used.
  • Examples of conditions that affect the binding between proteins (a) and (c) include temperature, Examples include medium type, protein (a) or (c) concentration, stirring intensity, coexistence time, gravity, and magnetic field.
  • the temperature at which the proteins (a) or (c) are brought into contact with each other can be set to 2 to 65 ° C, for example.
  • As the solvent for bringing the proteins (a) or (c) into contact with each other for example, PBS, TBS, Hepes buffer, etc. can be used.
  • the concentration of the protein (a) or (c) can be set to, for example, lng Zml to 1 OOmgZml.
  • the amount of binding between proteins (a) or (c) is, for example, the amount of binding between proteins (a) or (c), the amount of signal produced by the binding between proteins (a) or (c), etc. It can be measured as an index.
  • the amount of the conjugate between the proteins (a) or (c) is determined by, for example, adding a labeling substance to the protein (a) or (c) and bringing the proteins (a) or (c) into contact with each other. Thereafter, the conjugate of protein (a) or (c) can be separated, and the amount of labeling substance possessed by the conjugate can be measured as an index. Specifically, it can be measured using a known method such as the GST pull down method.
  • the amount of the conjugate between the proteins (a) and (c) is determined using a known protein analysis technique, for example, an antibody or fragment thereof that can react with the conjugate between the proteins (a) or (c). Western blotting method, immunoprecipitation method, ELISA, yarn and tissue immunostaining method, etc.
  • the “antibody” includes both monoclonal antibodies and polyclonal antibodies, and “monoclonal antibodies” and “polyclonal antibodies” include all classes of monoclonal antibodies and polyclonal antibodies.
  • “Antibody fragments” include Fab fragments, F (ab) ′ fragments, single-chain antibodies (scFv) and the like.
  • the type of signal generated by the binding between proteins (a) or (c) is not particularly limited.
  • reporter gene expression fluorescence energy transfer (FRET), surface plasmon resonance (SPR) or
  • FRET fluorescence energy transfer
  • SPR surface plasmon resonance
  • reporter gene examples include ⁇ -galactosidase gene, chloramphenicol acetyltransferase gene, luciferase gene, ampicillin resistance gene, tetracycline resistance gene, kanamycin resistance gene and the like.
  • Reporter activity includes, for example, j8 galactosidase activity, Chloramhue-Coleacetillan Examples include sulferase activity, luciferase activity, ampicillin resistance, tetracycline resistance, strength namicin resistance, and the like.
  • the second screening method of the present invention determines whether or not the test substance can suppress or promote the affinity interaction between the protein (a) or (d) and Baxinhibitor-1, and Screening a test substance capable of suppressing or promoting sex interaction as a substance affecting ontogenesis.
  • the affinity interaction between the protein (a) or (d) and Bax inhibitor-1 is considered to be involved in ontogeny, particularly ontogeny in the embryonic period.
  • a substance that can suppress or promote the affinity interaction between (d) and Bax inhibitor-1 it is possible to screen for substances that may affect ontogeny, particularly ontogenesis during the embryonic period.
  • test substance can suppress or promote the affinity interaction between the protein (a) or (d) and Bax inhibitor-1 can be determined, for example, as follows. It is not limited to this.
  • the amount of protein (a) or (d) and Bax inhibitor-1 bound after contacting protein (a) or (d) with Bax inhibitor-1 in the presence or absence of the test substance The amount of binding in the presence of the test substance is compared with the amount of binding in the absence of the test substance. As a result, if the amount of binding in the presence of the test substance is less than the amount of binding in the absence of the test substance, the test substance will interact with the protein (a) or (d) and Bax inhibitor-1. It can be determined that the action can be suppressed. On the other hand, if the amount of binding in the presence of the test substance is greater than the amount of binding in the absence of the test substance, the test substance has an affinity interaction between the protein (a) or (d) and Bax inhibitor-1. Can be determined to promote
  • a substance capable of suppressing or promoting the affinity interaction between protein (a) or (d) and Bax inhibitor-1 acts on one of protein (a) or (d) and Bax inhibitor-1. It may be a substance or a substance that acts on both.
  • a substance capable of inhibiting the affinity interaction between protein (a) or (d) and Bax inhibitor-1 binds to protein (a) or (d) in the dissociated state and Bax inhibitor-1.
  • the protein (a) or (d) and Bax inhibitor-1 may be contacted in vitro! Or in vivo.
  • a protein (a) or (d) When contacted in vivo, as a protein (a) or (d), (i) an endogenous protein present in the cell, (ii) a recombinant vector capable of expressing the target protein is introduced into the host cell.
  • a recombinant protein or the like present in the transformant produced by the introduction can be used. The same applies to Bax inhibitor-1.
  • the protein (a) or (d) is contacted with Bax inhibitor-1
  • the protein (a) or (d) is a wild type, mutant type, wild type or mutant type derivative, wild type or mutation.
  • a fusion protein of a mold with another protein or peptide can be used. The same applies to Bax inhibitor-1.
  • the temperature can be set to 2 to 65 ° C, for example.
  • the solvent for example, PBS, TBS, Hepes buffer, etc. can be used.
  • the concentration of the protein (a) or (d) can be set to, for example, lngZml to lOOmgZml.
  • the concentration of Bax inhibitor-1 can be set to, for example, lngZml to 100 mgZml.
  • the amount of binding between protein (a) or (d) and Bax inhibitor-1 is, for example, the amount of binding between protein (a) or (d) and Bax inhibitor-1 as in the amount of binding between proteins (a) or (c). inhibitor — binding to 1
  • the combined amount, the amount of signal produced by the binding of protein (a) or (d) and Bax inhibitor-1, etc. can be measured as indicators.
  • PCR polymerase chain reaction
  • 5 '— aagcagttccggttcggctccgagcagctgccg— 3' is used as a 5 'primer
  • 5' — ggcatctaagacacctagggggaacgc— 3 ' is used as a 3' primer
  • heat-resistant DN A polymerase (Expand Long Template PCR System, manufactured by Roche) 5 units, 200 ⁇ dNTP (dATP, dTTP, dCTP, dGTP), human lung tissue-derived cDNA 0.5 ng, and 1.75 mM magnesium chloride 94 after treatment for 10 minutes at ° C. C for 30 seconds, 62. C for 45 seconds, 68. Repeat 5 minutes with C for 35 cycles and 68 more. Processing for C10 minutes was performed.
  • Primers were designed as follows. In Drosophila, a homologous cDNA was searched from human EST based on the DNA sequence encoding a protein (GH24627p) that interacts with a receptor involved in developmental differentiation (etadyson receptor). Based on this cDNA sequence, 5'-RACE was performed using human testis-derived cDNA as a saddle, and a 5 'primer was designed based on the sequence obtained. The 3 'primer was designed assuming the human genome sequence.
  • the reaction solution was subjected to electrophoresis using 1% agarose gel (TBE buffer), and then the gel was stained with ethidium bromide and amplified by observing with a transilluminator. DNA fragments were detected. Furthermore, this DNA fragment was recovered from an agarose gel using a QUIAquick Gel Extraction Kit (manufactured by QUIAGEN), inserted into a multicloning site of a cloning vector plasmid such as pGEMTE, and then E. coli was used as a host. Amplified and sequenced. Cloning vector clone The insertion into the site was performed by TA clawing.
  • T thymidine
  • A adenine
  • the cultured Escherichia coli was recovered by centrifugation, and the plasmid was purified using a QIAGEN miniprep kit (manufactured by Qiagen).
  • the insertion sequence was determined using a fluorescent sequencer by the dye terminator method.
  • mouse gene 1 was isolated from mouse cDNA based on human gene 1.
  • Designed the RACE primer (5 and cttcggtcatggagaaggcccacgggatcct—3), and designed the mouse sperm-derived cDNA into a vertical shape.
  • 5'-RACE was performed, and 5 'primer (5—ccaaaggggccggagcgatgcccgctggtagccg—3) was set up from the obtained sequence.
  • puffima 5′—ctcattacagagagagagtcttcatcc—3, 15pmole each, heat resistance DNA polymerase (Ex pand Long Template PCR System, Roche) 5 units, 200 ⁇ 200 dNTP (dATP, dTTP, dCTP, dGTP), mouse sperm-derived cDNA 0.5 ng and 1.
  • the nucleotide sequence of human gene 1 is shown in SEQ ID NO: 1.
  • Human gene 1 contains an open reading frame encoding 478 amino acids.
  • the amino acid sequence of the protein encoded by human gene 1 is shown in SEQ ID NO: 2.
  • SEQ ID NO: 2 the 73rd amino acid part and the 140th amino acid part contain a peptide motif characteristic of a signaling factor called SAM (Sterile Alpha Motif) domain.
  • SAM Sterile Alpha Motif domain.
  • the Ser residue of the 52nd amino acid is included in the motif characteristic of the MAP kinase substrate, and the region from the 247th to the 250th amino acid (PPLP: Pro-Pro-Leu-Pro) is the SH3 binding region motif. is there.
  • SEQ ID NO: 3 shows the base sequence of mouse gene 1.
  • Mouse gene 1 contains an open reading frame encoding 478 amino acids.
  • the amino acid sequence of the protein encoded by mouse gene 1 is shown in SEQ ID NO: 4.
  • SAM Sterile Alpha Motif
  • the Ser residue at amino acid 52 is contained in a motif characteristic of the MAP kinase substrate, and the region from amino acid 247 to amino acid 250 (PPLP: Pro-Pro-Leu-Pro) is a SH3 binding region motif.
  • human gene 1 and mouse gene 1 showed homology of 89.5% at the DNA level and 90.2% at the protein level.
  • the genomic structure of human gene 1 was determined by homologous search of the cDNA sequence of human gene 1 with the published human genome sequence.
  • the genomic structure of mouse gene 1 was determined by homologous searching of the mouse gene 1 cDNA sequence against the published mouse genome sequence.
  • genomic structures of human gene 1 and mouse gene 1 are shown in FIG. As shown in FIG. 1, the genomic structures of human gene 1 and mouse gene 1 were very similar. In particular, all homologous exoregions had the same number of bases. Intron length was found to differ between human gene 1 and mouse gene 1.
  • Example 13 Human gene 1 expression tissue Nylon membrane blotted with polyA RNA prepared for human tissue, using 32 P-labeled human gene 1 as a probe in a hybridization buffer (ULTRAhyb Ultrasensitive Hybridization Buffer, Ambion) at 42 ° C After hybridization for 22 hours, the cells were washed with LS buffer (composition: 2XSSC, 0.1% SDS) or HS buffer (composition: 0.1% SSC, 0.1% SDS). Hybridized images were detected using an image analyzer (Fuji).
  • the expression of human gene 1 was confirmed in tissues such as brain, kidney, lung, muscle, placenta, small intestine, testis, adrenal gland, salivary gland, spleen, and stomach.
  • a gene expression vector 1 designed to produce a protein in which the human gene 1 product was fused to the C-terminus of GFP (Green Fluorescent Protein) in mammalian cells was constructed ( Figure 8).
  • a basic GFP vector designed so that expression of GFP fusion protein is induced in mammalian cells by CMV promoter by adding EcoRI-Notl site to the 3 'end of the GFP coding region cDNA was performed. Digested with restriction.
  • the human gene lcDNA was introduced with an EcoRI site at the 5 'end and a Notl site at the 3' end.
  • the gene fragment cleaved with both enzymes was ligated to the basic GFP vector digested with EcoRI and Notl, and the gene was introduced into Escherichia coli. Then, gene expression vector 1 was cloned.
  • Gene vector 1 was introduced into COS-7 cells using Fugene6 (Roche). That is, 1 ⁇ g of gene vector 1 and 3 ⁇ 1 of serum-free medium 100 1 containing Fugene6 (Roche) were mixed, allowed to stand at room temperature for 15 minutes, and then COS-7 was mixed 24 hours before. The gene was introduced by dripping and mixing into the best cell culture dish. The transfected COS-7 cells were cultured for 24 hours at 37 ° C in the presence of 5% CO. 1.5 in medium to stain cell nuclei 1106 ⁇ 13 33342 was added to the sample, incubated at 37 ° C for 10 minutes, and then washed 4 times with PBS.
  • Fugene6 Fugene6
  • the localization of the GFP-fused human gene 1 product in COS-7 cells was observed by fluorescence microscopy. As a result, as shown in FIG. 3, the GFP-fused human gene 1 product was found to exhibit a fibrous or vesicular structure in COS-7 cells.
  • Example 5 Detection of interaction between human gene 1 products by co-immunoprecipitation method A gene expression vector capable of expressing in a mammalian cell a protein in which a FLAG tag or HA tag was fused to the N-terminus of one human gene product was constructed (FIGS. 9 and 10). That is, a basic FLAG tag vector designed so that the expression of GFP fusion protein is induced in mammalian cells by CMV promoter, with EcoRI-Notl site attached to the 3, terminal part of FLAG tag cDNA. Restricted digest with EcoRI and Notl.
  • the gene expression vector for mammalian cells (PGAL4—human gene 1 vector, Fig. 11) and the human gene 1 product designed to be able to be expressed are fused to the C-terminal region of the VP 16 gene expression activation protein derived from Herpes Simplex Virus.
  • PVP16 human gene 1 vector, Fig. 12
  • the pGAL4—human gene 1 vector has an EcoRI—Sail site attached to the GAL4DNA binding region cDNA at the 3, end of the cDNA, and the early SV40 promoter allows expression of the GAL4DNA binding region fusion protein in mammalian cells.
  • a basic GAL4 vector designed to be induced was digested with EcoRI and Sail.
  • Human gene lcDNA is introduced into EcoRI site at 5 'end, Xhol site at 3' end and cleaved with both enzymes and ligated to EcoRI — Sail digested basic GAL4 vector, introduced into Escherichia coli, pGAL 4-human gene 1 vector cloned.
  • the pVP16-human gene 1 vector has an EcoRI-Notl site attached to the 3 'end of the VP16 transcriptional activation region cDNA, and expression of the VP16 transcriptional activation region fusion protein in mammalian cells using the CMV promoter.
  • the basic VP16 vector, designed to induce, was restriction digested with EcoRI and Notl.
  • the human gene lcDNA was ligated to the basic VP16 vector introduced with EcoRI and Notl at the 5 'end and Notl site at the 3' end and digested with both enzymes, and introduced into Escherichia coli.
  • PVP16—human gene 1 vector was cloned. These vectors were transfected into COS-7 cells. After incubation for 24 hours at 37 ° C in the presence of 5% CO
  • Gene expression vector for mammalian cells (PGAL4 human gene 1, Fig. 11) and human Bax inhibitor-1 gene product designed so that the human gene 1 product can be expressed by fusing to the C-terminal region of yeast-derived GAL4 DNA binding protein Constructed a gene expression vector for mammalian cells (pVP 16- Bax inhibitor-1, 13) designed to be fused and expressed in the C-terminal region of the Herpes Simplex Virus-derived VP 16 gene expression activity protein.
  • the pVP16-Bax inhibitor-1 vector has an EcoRI-Notl site attached to the 3 'end of the VP16 transcriptional activation region cDNA, and a VP16 transcriptional activity fusion region fusion protein in a mammalian cell by the CMV promoter.
  • a basic VP16 vector designed to induce expression of E. coli was digested with EcoRI and Notl.
  • Human Bax inhibitor A gene fragment that had an EcoRI site at the 5 'end and a Notl site at the 3' end, and a Notl site at the end and was cleaved with both enzymes was ligated to the basic VP16 vector digested with EcoRI and Notl, and introduced into E. coli.
  • Human Bax inhibitor-1 vector was cloned.
  • the base sequence of Bax inhibit or-1 gene is shown in SEQ ID NO: 5, and the amino acid sequence of Bax inhibitor-1 gene product is shown in SEQ ID NO: 6.
  • These vectors were transfected into COS-7 cells. 3 After culturing for 24 hours in the presence of 7 ° C and 5% CO, the cells are washed with PBS and luciferase activity
  • Cell lysate for measurement (25 mM TAE, ImM EDTA, 10% Glycerol, 1% TritonX 100, 2 mM DTT) was prepared, and the luciferase activity in the cell extract was measured with a luminometer in the presence of luciferin and ATP. .
  • ADSEVG-COOH was synthesized as a peptide
  • KLH Keyhole Limpet Hemocyanin
  • the mice were injected intramuscularly and subcutaneously into rabbits (2 birds) together with adjuvant. Further After 2 weeks, 5 weeks, 11 weeks, and 17 weeks, the peptide and adjuvant mixture was also injected, and antisera was prepared 25 weeks after the first antigen injection.
  • the FLAG tag-human gene 1 product was transiently expressed in HEK 293T cells, treated with SDS-PAGE sample buffer, and then separated by SDS-PAGE electrophoresis and transferred to a nitrocellulose membrane. Was under 1 hour at room temperature the membranes in blocking buffer (0.
  • an antigen-specific band was detected in the HEK293T cell-extracted protein lane in which human gene 1 was forcibly expressed.
  • the 5 ′ genomic DNA containing the first and second exons of mouse gene 1 and the 3 ′ genomic DNA containing the second exon and the third and fourth exons PCR amplification was performed with a restriction enzyme site added. That is, the 5 'genomic DNA containing part of the first and second exons is 5, the primer (5'-gactcgtcctcttcagtgctggatgtaggc gtg-3') and the 3 'primer designed with the Sail site attached.
  • the mouse gene 1 gene targeting vector was made double-stranded by digestion with restriction enzyme Notl and introduced into mouse ES cells by electroporation. Select the cells at 37 ° C, 5% CO
  • the cells were cultured in the presence of G418 and ganciclovir, which are two selective drugs. Resistant cell colonies were also prepared with genomic DNA, and homologous recombination-positive ES cells were selected by PCR, Southern nose and hybridization. Positive ES cells were introduced into blastocysts by microinjection and then transplanted into pseudopregnant female mice. The resulting chimeric mouse was bred with a wild-type mouse, and the resulting baby was genotyped using the agouti hair color as a marker to produce a heterozygous mouse deficient in gene 1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne une protéine innovante qui participe à l'ontogénie. La protéine est l'une quelconque des protéines (a) à (d) suivantes : (a) protéine comprenant la séquence d'acides aminés décrite sous les SEQ ID NO : 2 ou 4 ; (b) protéine qui comprend une séquence d'acides aminés présentant la délétion, la substitution ou l'addition d'un ou plusieurs résidus d'acides aminés dans la séquence d'acides aminés décrite sous les SEQ ID NO : 2 ou 4 et qui est essentielle pour l'ontogénie ; (c) protéine qui comprend une séquence d'acides aminés présentant la délétion, la substitution ou l'addition d'un ou plusieurs résidus d'acides aminés dans la séquence d'acides aminés décrite sous les SEQ ID NO : 2 ou 4 et qui présente une interaction par affinité avec la protéine (a) ; et (d) protéine qui comprend une séquence d'acides aminés présentant la délétion, la substitution ou l'addition d'un ou plusieurs résidus d'acides aminés dans la séquence d'acides aminés décrite sous les SEQ ID NO : 2 ou 4 et qui présente une interaction par affinité avec l'inhibiteur-1 de Bax.
PCT/JP2006/322879 2005-11-16 2006-11-16 Proteine innovante et gene codant pour la proteine Ceased WO2007058267A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005331505A JP2007135441A (ja) 2005-11-16 2005-11-16 新規タンパク質及びそれをコードする遺伝子
JP2005-331505 2005-11-16

Publications (2)

Publication Number Publication Date
WO2007058267A1 true WO2007058267A1 (fr) 2007-05-24
WO2007058267A8 WO2007058267A8 (fr) 2008-02-14

Family

ID=38048651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/322879 Ceased WO2007058267A1 (fr) 2005-11-16 2006-11-16 Proteine innovante et gene codant pour la proteine

Country Status (2)

Country Link
JP (1) JP2007135441A (fr)
WO (1) WO2007058267A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009112439A1 (fr) * 2008-03-10 2009-09-17 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines comme inhibiteurs de plk kinases
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8492377B2 (en) 2006-07-13 2013-07-23 Janssen Pharmaceutica Nv MTKI quinazoline derivatives
US8772272B2 (en) 2003-12-18 2014-07-08 Janssen Pharmaceutica Nv Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents
US9688691B2 (en) 2004-12-08 2017-06-27 Janssen Pharmaceutica Nv Macrocyclic quinazole derivatives and their use as MTKI
WO2021103733A1 (fr) * 2019-11-28 2021-06-03 西北农林科技大学 Souche de brucella suis avec délétion du gène bi-1, son procédé de construction et son utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022833A1 (fr) * 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridylfurans et pyrroles inhibiteurs de la kinase raf

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362586A1 (en) * 2001-07-17 2003-04-07 Incyte Genomics, Inc. Receptors and membrane-associated proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022833A1 (fr) * 2001-09-05 2003-03-20 Smithkline Beecham Plc Pyridylfurans et pyrroles inhibiteurs de la kinase raf

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772272B2 (en) 2003-12-18 2014-07-08 Janssen Pharmaceutica Nv Pyrido-and pyrimidopyrimidine derivatives as anti-proliferative agents
US8933067B2 (en) 2003-12-18 2015-01-13 Janssen Pharmaceutica Nv Pyrido and pyrimidopyrimidine derivatives as anti-profilerative agents
US9688691B2 (en) 2004-12-08 2017-06-27 Janssen Pharmaceutica Nv Macrocyclic quinazole derivatives and their use as MTKI
US10208062B2 (en) 2004-12-08 2019-02-19 Janssen Pharmaceutica Nv Macrocyclic quinazole derivatives and their use as MTKI
US8492377B2 (en) 2006-07-13 2013-07-23 Janssen Pharmaceutica Nv MTKI quinazoline derivatives
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
WO2009112439A1 (fr) * 2008-03-10 2009-09-17 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines comme inhibiteurs de plk kinases
US8318929B2 (en) 2008-03-10 2012-11-27 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines
US8609836B2 (en) 2008-03-10 2013-12-17 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines
WO2021103733A1 (fr) * 2019-11-28 2021-06-03 西北农林科技大学 Souche de brucella suis avec délétion du gène bi-1, son procédé de construction et son utilisation

Also Published As

Publication number Publication date
JP2007135441A (ja) 2007-06-07
WO2007058267A8 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
JP3462498B2 (ja) レセプターチロシンキナーゼ標的タンパク質のｃＤＮＡクローニング方法及びｈＧＲＢタンパク質
US7314621B2 (en) Cytidine deaminase
JPH09510861A (ja) 新規な蛋白質チロシンホスファターゼに対するヌクレオチド配列の一次構造および機能性発現
JP2000512482A (ja) 新規ｐｔｐ２０、ｐｃｐ―２、ｂｄｐ―１、ｃｌｋ、およびｓｉｒｐタンパク質並びに関連する生成物および方法
KR100633221B1 (ko) 신규 콜렉틴
WO2007058267A1 (fr) Proteine innovante et gene codant pour la proteine
JP4201712B2 (ja) Ｇｉｐ、グッドパスチャー抗原結合タンパク質と相互作用する転写因子活性を備えたポリペプチドのファミリー
JP4508872B2 (ja) 遺伝子転写調節剤
US20050171336A1 (en) Murine ortholog of the human disrupted-in-schizophrenia 1 gene
US7029912B1 (en) Tyrosine kinase substrate(Tks) proteins
JP5099534B2 (ja) Ｋａｎｋ３遺伝子の癌治療及び癌検出並びに創薬への利用
US5840536A (en) Growth factor receptor-binding insulin receptor
JP5099535B2 (ja) Ｋａｎｋ４遺伝子の癌治療及び癌検出並びに創薬への利用
WO1999023218A1 (fr) PROTEINES DE FIXATION DE p16, GENE DE CES PROTEINES ET ANTICORPS CONTRE CES PROTEINES
WO1997020573A1 (fr) Homologue de proteine 2 se liant au recepteur du facteur de croissance
EP1030859A1 (fr) Proteine fixatrice de ras (pre1)
JP5114765B2 (ja) Ｋａｎｋ２遺伝子の癌治療及び癌検出並びに創薬への利用
JP4301541B2 (ja) Ｓｍｇ−１結合タンパク質及びその活性を制御する物質のスクリーニング方法
JP2004530427A (ja) アカゲザルアンドロゲン受容体をコードするｄｎａ分子
JP2003523181A (ja) Ｄｎａヘリカーゼ、ヒトｎｈｌをコードするｄｎａ分子
US20060019294A1 (en) Tyrosine kinase substrate (Tks) proteins
JP2003144168A (ja) 核外移行機能又は核−細胞質間移行機能を有する細胞周期関連タンパク質
JP2004073142A (ja) Ｇａｎｐ結合性タンパク質
JPWO2001025425A1 (ja) 核局在性ＲｅｃＱ５型ＤＮＡヘリカーゼ
EP1533378A2 (fr) tks7, une proteine de substrat de tyrosine kinase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06832759

Country of ref document: EP

Kind code of ref document: A1